Search company, investor...

Ideal Medical Technologies

Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 10 mos ago

About Ideal Medical Technologies

Ideal Medical Technologies is a company that aims to improve healthcare through technological innovation. The company's initial project will be the creation of an artificial pancreas for use in the hospital setting. This device will utilize an artificial intelligence-based glucose controller to provide optimal glucose control for both diabetic patients and ICU patients. The company was founded in 2013 and is based in Asheville, North Carolina.

Headquarters Location

18 N Kensington Rd

Asheville, North Carolina, 28804,

United States


Missing: Ideal Medical Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ideal Medical Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ideal Medical Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ideal Medical Technologies is included in 5 Expert Collections, including Digital Health.


Digital Health

21,956 items

Startups recreating how healthcare is delivered


Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



2,046 items


Health IT

7,901 items

Ideal Medical Technologies Patents

Ideal Medical Technologies has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Neurotrauma, Surgical removal procedures, Intensive care medicine, Respiratory therapy, Psychiatric diagnosis


Application Date


Grant Date



Related Topics

Neurotrauma, Surgical removal procedures, Intensive care medicine, Respiratory therapy, Psychiatric diagnosis



Latest Ideal Medical Technologies News

Ideal Medical Receives Approval for Second Phase of First in Man Safety Study

Nov 9, 2022

News provided by Share this article Share this article ASHEVILLE, N.C., Nov. 9, 2022 /PRNewswire/ -- Ideal Medical Technologies (IMT), developer of FUSION, a fully autonomous closed loop artificial pancreas system designed for use in the ICU setting, announced today that the U.S. Food and Drug Administration (FDA) has approved the second phase of its first in man safety study at Emory University Hospital. Recognized by the FDA with Breakthrough Medical Device status, FUSION's AI based glucose control system has the potential to dramatically impact patient outcomes, reduce nursing burden, and significantly reduce costs. The first in man safety study began earlier this year, and the FDA's review of data from the first patient group demonstrated FUSION's ability to maintain glucose in the range of 70-180 mg/dL 97% of the time with 0% <70 mg/dL. Coefficient of variation was 20%. "These impressive results represent a significant milestone for the company and demonstrate the feasibility of autonomous glucose management in the hospital setting," said Dr. Leon DeJournett, IMT's founder and Chief Medical Officer. "I am excited to be bringing this technology to fruition as more precise glucose management in the ICU has the potential to revolutionize patient care and outcomes, and the success of FUSION can point the way forward to better regulation of other bodily systems in the future." IMT intends to complete the first in man safety study by the end of 2022 and initiate the next safety study in ICU patients in Q1 2023. IMT is planning to bring the FUSION system to the hospital market in mid 2024. About IMT  Ideal Medical Technologies, incorporated in Delaware in September 2014, is a highly innovative medical device company focused on the development and sale of an Artificial Pancreas System for use in both the ICU and general ward settings. The U.S. FDA has granted Breakthrough Medical Device status to IMT's FUSION system, which should help to expedite regulatory approval. For more information about IMT and FUSION, visit . Contact:

Ideal Medical Technologies Frequently Asked Questions (FAQ)

  • When was Ideal Medical Technologies founded?

    Ideal Medical Technologies was founded in 2013.

  • Where is Ideal Medical Technologies's headquarters?

    Ideal Medical Technologies's headquarters is located at 18 N Kensington Rd, Asheville.

  • What is Ideal Medical Technologies's latest funding round?

    Ideal Medical Technologies's latest funding round is Loan.

  • How much did Ideal Medical Technologies raise?

    Ideal Medical Technologies raised a total of $450K.

  • Who are the investors of Ideal Medical Technologies?

    Investors of Ideal Medical Technologies include North Carolina Biotechnology Center.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.